Related Experiment Video
Updated: Jun 26, 2025
14:57
Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
9.5K
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-2024 update
Jitka Malcikova1,2, Sarka Pavlova1,2, Panagiotis Baliakas3
1Department of Internal Medicine, Hematology and Oncology, and Institute of Medical Genetics and Genomics, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic.
Leukemia
|May 16, 2024
Summary
Updated guidelines for TP53 analysis in chronic lymphocytic leukemia (CLL) emphasize thorough method validation over specific variant allele frequency cut-offs for detecting TP53 mutations. These recommendations aim to improve patient management and clinical trial stratification.
Area of Science:
- Hematology
- Molecular Diagnostics
- Oncology
Background:
- TP53 aberrations are critical in chronic lymphocytic leukemia (CLL) treatment decisions.
- Previous European Research Initiative on CLL (ERIC) guidelines for TP53 analysis in CLL were published in 2018.
- Technological advancements necessitate updated TP53 analysis recommendations.
Purpose of the Study:
- To provide updated recommendations for TP53 analysis in CLL.
- To address the detection of low-burden TP53-mutated clones.
- To improve the interpretation and reporting of TP53 aberration results.
Main Methods:
- Review of current knowledge on TP53 mutations in CLL.
- Discussion of methodological aspects for introducing next-generation sequencing (NGS).
- Development of a simplified algorithm for TP53 variant classification.
Main Results:
- A specific variant allele frequency (VAF) cut-off for reporting TP53 mutations is no longer recommended.
- Emphasis on thorough method validation by reporting laboratories.
- A consensus-based algorithm for TP53 variant classification in CLL is provided.
Conclusions:
- Updated recommendations assist diagnosticians in accurate TP53 mutation status assessment.
- Improved understanding of lab reports by physicians will reduce misinterpretation and incorrect patient management.
- Enhanced patient stratification in clinical trials is expected.
